MCL1
ENSG00000143384
Target class
Other cytosolic protein
Chromosome
1
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- MCL1
- Gene name
- MCL1 apoptosis regulator, BCL2 family member
- Gene symbol
- MCL1
- Protein name
- Induced myeloid leukemia cell differentiation protein Mcl-1 (Bcl-2-like protein 3) (Bcl2-L-3) (Bcl-2-related protein EAT/mcl1) (mcl1/EAT)
- BCL2L3
- Mcl-1
- Gene biotype
- Protein coding
- Gene family
- BCL2 family
- Target class
- Other cytosolic protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 474.74
- Tissue specificity (Gini)
- 0.337
- Tissue specificity (tau)
- 0.641
- KEGG gene identifiers
- hsa:4170
- Protein interaction confidence
- 0.832684
- Protein interaction partners
- 76
- R-HSA-6785807
- R-HSA-9725370
- End position
- 150579738
- Start position
- 150560895
- Chromosome
- 1
- Strand
- Reverse
- Membrane
- Single-pass membrane protein . Cytoplasm. Mitochondrion. Nucleus, nucleoplasm. Note=Cytoplasmic, associated with mitochondria.
- Mitochondria
- Tissue specificity (tau)
- 0.640645
- Expression inequality (Gini)
- 0.337079
Expression in transcripts per million
- Lung
- 474.74
- Artery - Aorta
- 384.63
- Whole Blood
- 376.55
- Adipose - Visceral (Omentum)
- 364.87
- Cells - Cultured fibroblasts
- 313.95
Expression in transcripts per million
- Lung474.74
- Artery - Aorta384.63
- Whole Blood376.55
- Adipose - Visceral (Omentum)364.87
- Cells - Cultured fibroblasts313.95
- Artery - Coronary309.89
- Skin - Not Sun Exposed (Suprapubic)298.59
- Nerve - Tibial293.96
- Spleen283.05
- Skin - Sun Exposed (Lower leg)272.28
- Artery - Tibial258.96
- Esophagus - Mucosa250.97
- Cells - EBV-transformed lymphocytes246.51
- Breast - Mammary Tissue241.31
- Vagina241.31
- Fallopian Tube237.9
- Esophagus - Gastroesophageal Junction227.8
- Adipose - Subcutaneous226.95
- Esophagus - Muscularis224.06
- Thyroid218.58
- Uterus211.45
- Colon - Sigmoid206.08
- Small Intestine - Terminal Ileum200.19
- Minor Salivary Gland197.91
- Bladder195.03
And 29 more, listed on the interactive page.
- GO:0006974
- GO:0010507
- GO:0034097
- GO:0043065
- GO:0043066
- GO:0097192
- GO:1903378
- GO:2000811
- GO:2001240
- GO:0005634
- GO:0005737
- GO:0005739
- GO:0005741
- GO:0005829
- GO:0016020
- GO:0097136
- GO:0005515
- GO:0008320
- GO:0046982
- GO:0051434
Related records
Trials (723)
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
- a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
- A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
- A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
- A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
- A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
- A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Drugs (4)
- AZD-5991
- Obatoclax Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitor
- Obatoclax mesylate Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitor
- Venetoclax